Advancing medication development for alcohol use disorder: A narrative review integrating preclinical, human laboratory, and clinical trials
Alcohol, Clinical and Experimental Research · 2025-12 · 49 (12) · 2649-2659
DOI: 10.1111/acer.70181 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alcohol, Clinical and Experimental Research, online erschienen am 13.10.2025. Verfasst von Steven J Nieto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Alcoholism, Drug Development, Alcohol Deterrents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Medication development for alcohol use disorder (AUD) represents a challenging, costly, and time‐consuming process. A typical development trajectory involves testing compounds in animal models, human laboratory studies, and randomized clinical trials (RCTs). This paper reviews a series of data‐driven studies seeking to evaluate best practices in medication development for AUD at each of the three levels of analysis. First, we evaluate the role of behavioral pharmacology paradigms in early efficacy testing and highlight the importance of preclinical and human laboratory evidence in making critical “go/no‐go” decisions throughout the development process. Second, we discuss a recent translational meta‐analytic approach that integrates preclinical, human laboratory, and RCT data to inform AUD medication development. This narrative review synthesizes findings from systematic reviews, meta‐regression analyses, and integrated data across stages of medication testing. Findings from this work suggest that factors such as sample characteristics and study design influence the detection of medication effects on AUD outcomes, emphasizing the need for standardized methodologies. Furthermore, findings suggest that early efficacy signals in animal models and human laboratory studies can predict specific clinical trial outcomes, offering valuable insights for data‐informed decision making in medication development. Together, these studies bridge the gap between the preclinical and clinical stages, facilitating more efficient medication development for AUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.
- Department of Psychology, University of California, Los Angeles, California, USA.
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA.
ORCID-Profile: Steven J Nieto, Lara A Ray
Förderung
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Nieto, S. J., & Ray, L. A. (2025). Advancing medication development for alcohol use disorder: A narrative review integrating preclinical, human laboratory, and clinical trials. Alcohol, Clinical and Experimental Research, 49(12), 2649-2659. https://doi.org/10.1111/acer.70181
Vancouver
Nieto SJ, Ray LA. Advancing medication development for alcohol use disorder: A narrative review integrating preclinical, human laboratory, and clinical trials. Alcohol, Clinical and Experimental Research. 2025;49(12):2649-2659. doi:10.1111/acer.70181
BibTeX
@article{Nieto2025,
author = {Nieto, Steven J and Ray, Lara A},
title = {Advancing medication development for alcohol use disorder: A narrative review integrating preclinical, human laboratory, and clinical trials},
journal = {Alcohol, Clinical and Experimental Research},
year = {2025},
volume = {49},
number = {12},
pages = {2649--2659},
doi = {10.1111/acer.70181}
}
EUVIMED